Aug 30, 2026•1 min read
FDA Approves ANDA076885 for Rabeprazole Sodium
FDA has approved ANDA076885 for Rabeprazole Sodium oral delayed‑release tablets (20 mg) sponsored by Pharmobedient, with multiple labeling submissions approved between 2013 and 2023.